Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

DA-R-EPOCH in Post Transplant Lymphoproliferative Disorders (PTLD) and EBV-Positive High Grade B-Cell Lymphomas with Rearrangements of MYC and BCL2 (HGBL)

Patrick D. Ford, PharmD, Alexandra E. Kovach, MD, John P. Greer, MD, David S. Morgan, MD, Mahsa Sharifi Talbott, PharmD, Nishitha Reddy, MD MSCI, MBBS

Blood (2016) 128 (22): 1875.

https://doi.org/10.1182/blood.V128.22.1875.1875

Published: 2016

Journal Articles

A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Andre Goy, MD, Radhakrishnan Ramchandren, MD, Nilanjan Ghosh, MD PhD, Javier Munoz, MD, David S. Morgan, MD, Nam H. Dang, MD PhD, Mark Knapp, MD, Maria Delioukina, MD, Edwin C. Kingsley, MD, Anh Tran, BS, Jerry Ping, PhD, Darrin M. Beaupre, MD PhD, Jutta K. Neuenburg, MD PhD, Jia Ruan, MD PhD

Blood (2016) 128 (22): 473.

https://doi.org/10.1182/blood.V128.22.473.473

Published: 2016

Journal Articles

Correlation of Toll-like Receptor (TLR) and PD-1 Pathways in Central Nervous System Lymphoma: A Clinicopathological Study on Outcomes

Tarsheen Sethi, MD MBBS, Alexandra E. Kovach, MD, Samuel M Rubinstein, MD, Laura Lee, MDPhD, Yang Wang, PhD, David S. Morgan, MD, John P Greer, MD, Cindy Vnencak-Jones, PhD, Nishitha Reddy, MD MSCI, MBBS

Blood (2016) 128 (22): 929.

https://doi.org/10.1182/blood.V128.22.929.929

Published: 2016

Journal Articles

Interim Absolute Lymphocyte Count (ALC) As a Predictor of Survival in Hodgkin Lymphoma

Tarsheen K. Sethi, MD MS, Van T Nguyen, MD, David S Morgan, MD, John P. Greer, MD, Nishitha M Reddy, M.B.B.S.

Blood (2015) 126 (23): 2640.

https://doi.org/10.1182/blood.V126.23.2640.2640

Published: 2015

Journal Articles

Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL

Tarsheen K. Sethi, MD MS, Van T Nguyen, MD, Shaoying Li, MD, David S Morgan, MD, John P. Greer, MD, Nishitha M Reddy, M.B.B.S.

Blood (2015) 126 (23): 1441.

https://doi.org/10.1182/blood.V126.23.1441.1441

Published: 2015

Journal Articles

Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab Following Standard Chemotherapy for Patients with Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL) - Final Results

Nishitha M Reddy, M.B.B.S., David S Morgan, MD, John P Greer, Heidi Chen, Steven I. Park, MD, Kristy L. Richards, PhD MD

Blood (2015) 126 (23): 2739.

https://doi.org/10.1182/blood.V126.23.2739.2739

Published: 2015

Journal Articles

Combined Modality Approach for Early Stage Unfavorable Hodgkin Lymphoma- Can We Avoid Radiation Therapy Based on Interim PET Imaging?

Van T Nguyen, MD, Judy P Tsai, MD, John P Greer, MD, David S Morgan, MD, Nishitha M Reddy, M.B.B.S.

Blood (2014) 124 (21): 5430.

https://doi.org/10.1182/blood.V124.21.5430.5430

Published: 2014

Journal Articles

Role Of Aggressive Chemotherapeutic Regimens In Double Hit Lymphoma- Can Alternate Aggressive Induction Regimens Overcome The Poor Prognosis Of Diffuse Large B Cell Lymphoma?

Judy Tsai, M.D., John P Greer, MD, David S. Morgan, MD, Shaoying Li, MD, Nishitha M. Reddy, MD

Blood (2013) 122 (21): 4361.

https://doi.org/10.1182/blood.V122.21.4361.4361

Published: 2013

Journal Articles

A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant: Final Results After Early Trial Discontinuation

Bastian von Tresckow, MD, Aleksander Skotnicki, MD, PhD, Igur Lisukov, MD, Shivani Srivastava, MD, David S. Morgan, MD, Franck Morschhauser, MD, PhD, Caterina Stelitano, Jeffrey Szer, BMedSc, MBBS, FRACP, Dennis A. Eichenauer, MD, Jeremy S. Abramson, MD, Anna Sureda, MD, PhD, Christophe Ferme, MD, Andreas Engert, MD

Blood (2013) 122 (21): 4648.

https://doi.org/10.1182/blood.V122.21.4648.4648

Published: 2013

Journal Articles

Phase II Randomized Study Of Lenalidomide Or Lenalidomide and Rituximab As Maintenance Therapy Following Standard Chemotherapy For Patients With Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Nishitha M. Reddy, MD, David S. Morgan, MD, Steven I. Park, MD, John P Greer, MD, Kristy L. Richards, MD PhD

Blood (2013) 122 (21): 3061.

https://doi.org/10.1182/blood.V122.21.3061.3061

Published: 2013

Journal Articles

Comparison of Autologous Vs. Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma

Nishitha M. Reddy, MD, Olalekan O Oluwole, MBBS, MPH, John P Greer, MD, David S Morgan, MD, Stacey Goodman, MD, Brian Engelhardt, MD, Wichai Chinratanalab, MD, Adetola A Kassim, MD, Madan Jagasia, MBBS, MS, Bipin N. Savani, MD

Blood (2012) 120 (21): 2036.

https://doi.org/10.1182/blood.V120.21.2036.2036

Published: 2012

Journal Articles

A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab As Maintenance Therapy Following R-CHOP Chemotherapy for Patients with High Risk Diffuse Large B-Cell Lymphoma

Nishitha M. Reddy, MD, Rhea M Simons, RN, Meghan E Caldwell, NP, Heidi Chen, PhD, Madan Jagasia, MBBS, MS, David S Morgan, MD, Steven I. Park, MD, John P Greer, MD, Kristy L. Richards, PhD, MD

Blood (2012) 120 (21): 3668.

https://doi.org/10.1182/blood.V120.21.3668.3668

Published: 2012

Journal Articles

Combination Chemotherapy with Rituximab, Gemcitabine, Vinorelbine and Liposomal Doxorubicin As a Salvage Regimen for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Patrick L Stevens, MD, Mahsa Talbott, Meghan E Caldwell, NP, David S Morgan, MD, Annette S. Kim, MD, PhD, John P Greer, MD, Nishitha M. Reddy, MD

Blood (2011) 118 (21): 4954.

https://doi.org/10.1182/blood.V118.21.4954.4954

Published: 2011

Journal Articles

Predictive Value for Engraftment and Survival of Total Nucleated Cell Dose (TNC) as Compared to CD34 + Cell Dose after Autologous and Allogeneic Bone Marrow Transplant (BMT) for Hematologic Malignancies.

Adetola A. Kassim, MD, Shin Mineishi, MD, Madan Jagasia, MD, Madhuri Vurisikala, MD, Stacey Goodman, MD, John P. Greer, MD, Wichai Chinratanalab, MD, Katherine Ruffner, MD, David S. Morgan, MD, Richard S. Stein, MD, Stephen Brandt, MD, Friedrich G. Schuening, MD

Blood (2004) 104 (11): 5055.

https://doi.org/10.1182/blood.V104.11.5055.5055

Published: 2004

Journal Articles

Post-Transplant Positron Emission Tomography Using Fluorine 18-Fluoro-Deoxyglucose ([ 18 F]FDG-PET) Correlates with Outcome in Patients with Aggressive Non-Hodgkin’s Lymphoma Undergoing High Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation (HDC/ASCT).

Adetola A. Kassim, MD, Shin Mineishi, MD, John P. Greer, MD, Natalie McVay, Tatsuki Koyama, PhD, Wichai Chinratanalab, MD, Stephen J. Brandt, MD, Madan Jagasia, MD, Katherine Ruffner, MD, Friedrich G. Schuening, MD, Richard S. Stein, MD, Madhuri Vusirikala, MD, Stacey Goodman, MD, David S. Morgan, MD

Blood (2004) 104 (11): 906.

https://doi.org/10.1182/blood.V104.11.906.906

Published: 2004

NARROW

DA-R-EPOCH in Post Transplant Lymphoproliferative Disorders (PTLD) and EBV-Positive High Grade B-Cell Lymphomas with Rearrangements of MYC and BCL2 (HGBL)

A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Correlation of Toll-like Receptor (TLR) and PD-1 Pathways in Central Nervous System Lymphoma: A Clinicopathological Study on Outcomes

Interim Absolute Lymphocyte Count (ALC) As a Predictor of Survival in Hodgkin Lymphoma

Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL

Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab Following Standard Chemotherapy for Patients with Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL) - Final Results

Combined Modality Approach for Early Stage Unfavorable Hodgkin Lymphoma- Can We Avoid Radiation Therapy Based on Interim PET Imaging?

Role Of Aggressive Chemotherapeutic Regimens In Double Hit Lymphoma- Can Alternate Aggressive Induction Regimens Overcome The Poor Prognosis Of Diffuse Large B Cell Lymphoma?

A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant: Final Results After Early Trial Discontinuation

Phase II Randomized Study Of Lenalidomide Or Lenalidomide and Rituximab As Maintenance Therapy Following Standard Chemotherapy For Patients With Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Comparison of Autologous Vs. Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma

A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab As Maintenance Therapy Following R-CHOP Chemotherapy for Patients with High Risk Diffuse Large B-Cell Lymphoma

Combination Chemotherapy with Rituximab, Gemcitabine, Vinorelbine and Liposomal Doxorubicin As a Salvage Regimen for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Predictive Value for Engraftment and Survival of Total Nucleated Cell Dose (TNC) as Compared to CD34 + Cell Dose after Autologous and Allogeneic Bone Marrow Transplant (BMT) for Hematologic Malignancies.

Post-Transplant Positron Emission Tomography Using Fluorine 18-Fluoro-Deoxyglucose ([ 18 F]FDG-PET) Correlates with Outcome in Patients with Aggressive Non-Hodgkin’s Lymphoma Undergoing High Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation (HDC/ASCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only